source
- FDA clears Lantheus' Tauklarify PET imaging agent for Alzheimer’s tau detectionLantheus received FDA clearance for its PET imaging agent Tauklarify, also known as MK-6240, which is designed to help diagnose Alzheimer’s disease by visualizing tau protein deposits. The clearan…
- Slate Medicines to merge with Fulcrum Therapeutics after Fulcrum drops sickle-cell drugSlate Medicines announced it will combine with Fulcrum Therapeutics in a reverse merger, giving the struggling biotech a new corporate home. Fulcrum had been developing pociredir, a therapy design…